Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?

V2, Crosslink

🧫

Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-amyloid-

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Mechanism: Why Does Amyloid Removal Only Slow Decline 27%? ## Background and Rationale The recent clinical approval of amyloid-clearing antibodies lecanemab and donanemab represents a significant milestone in Alzheimer's disease therapeutics, yet their modest clinical efficacy—approximately 27% slowing of cognitive decline despite achieving near-complete plaque removal—reveals a fundamental gap in our understanding of AD pathogenesis. This paradox suggests that while amyloid-beta accumulation

METHODOLOGY NOTES

**Study Design and Patient Cohort Recruitment** A prospective, longitudinal observational study enrolling 500 early-stage Alzheimer's disease patients (CDR 0.5-1.0, MMSE 20-26) receiving FDA-approved amyloid-clearing monoclonal antibodies (lecanemab or donanemab) across 15 tertiary medical centers. Stratification occurs by: (1) APOE4 genotype (ε4+/ε4-), (2) age quartiles (55-65, 65-75, 75-85, >85 years), (3) baseline cognitive scores (ADAS-Cog13 tertiles), and (4) amyloid PET burden (SUVr >1.3 or ≤1.3). Baseline assessment includes neuropsychological testing (ADAS-Cog13, CDR-SB, MMSE), genetic profiling (whole genome sequencing), structural and functional neuroimaging (3T MRI with DTI, resting-state fMRI), and blood/CSF biomarker collection within 2 weeks pre-treatment initiation. **Multi-Omics Biofluid and Tissue Analysis Pipeline** Longitudinal CSF sampling occurs at baseline, 6, 12, 24, and 36 months post-treatment initiation via lumbar puncture. Each 12-mL CSF aliquot undergoes: (

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.897345Z'}
summary	# Mechanism: Why Does Amyloid Removal Only Slow Decline 27%? ## Background and Rationale The recent clinical approval of amyloid-clearing antibodies lecanemab and donanemab represents a significant mi
entities	{'genes': ['BCL2L1/C1Q/C3'], 'diseases': ["Alzheimer's Disease"]}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	Quantify the relative contribution of non-amyloid molecular mechanisms to cognitive decline progression in Alzheimer's patients receiving antibody treatment
methodology_notes	Study Design and Patient Cohort Recruitment A prospective, longitudinal observational study enrolling 500 early-stage Alzheimer's disease patients (CDR 0.5-1.0, MMSE 20-26) receiving FDA-approved
replication_status	single_study
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.897350', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

650

Outgoing

602

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?

derives from (13)

supports (4)

💬 Discussion